Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study (MSAJOY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01044992|
Recruitment Status : Completed
First Posted : January 8, 2010
Last Update Posted : February 26, 2010
Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy. The objective of the study is to assess right-hand motor activation in MSA patients before and after an acute levodopa challenge and to compare these data with those obtained in patients with Parkinson Disease (PD) and healthy volunteers (HV).
Methods: Eighteen MSA patients, eight PD patients and 10 age-matched HV will be included. rCBF measurements with H215O PET will be performed at rest and during a right hand movement. Statistical parametric mapping will be used to analyze motor versus rest in OFF and ON condition and effect of levodopa on motor activation.
Hypothesis: MSA and PD patient should recruited different motor networks.
|Condition or disease||Intervention/treatment||Phase|
|Multisystemic Atrophy||Radiation: H215O PET Drug: Levodopa||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge|
|Study Start Date :||May 2002|
|Actual Primary Completion Date :||May 2005|
|Actual Study Completion Date :||May 2006|
U.S. FDA Resources
Experimental: Drug and radiation
Levodopa and H215O PET
Radiation: H215O PET
H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
Other Name: To measure rCBF, 300 MBq of H215O will be administered for each 80-second emission scan.Drug: Levodopa
Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
- The "movement effect" consists of comparing the images obtained during hand movement with those acquired at rest for each group (MSA, PD and Healthy subjects) using the Family Wise Error (FWE) statistical threshold in OFF and ON conditions
- Difference between motor activation of the three groups in OFF condition
- Difference between motor activation during OFF and ON condition in each group reflecting levodopa effect on motor activation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01044992
|Bordeaux, France, 33|
|Clermont-Ferrand, France, 63003|
|Marseille, France, 13000|
|Toulouse, France, 31059|
|Study Director:||Olivier Rascol, MD PHD||University Hospital, Toulouse|
|Study Director:||Pierre Payoux, MD PhD||University Hospital, Toulouse|
|Principal Investigator:||Olivier Rascol, MD PhD||University Hospital, Toulouse|
|Principal Investigator:||Franck Durif, MD PhD||University Hospital, Clermont-Ferrand|
|Principal Investigator:||Jean-Philippe Azulay, MD PhD||University Hospital, Marseille|
|Principal Investigator:||François Tison, MD PhD||University Hospital, Bordeaux|